News Industry News Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death October 02, 2017
News Industry News U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin) January 24, 2016
News Industry News Leading health organizations collaborate with industry on new initiative to combat growing diabetes and cardiovascular disease threat